Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Paul Pfeffer, Nasloon Ali, Ruth Murray, et al.
Allergy (2023) Vol. 78, Iss. 7, pp. 1934-1948
Open Access | Times Cited: 15

Showing 15 citing articles:

Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Michael E. Wechsler, Ghislaine Scélo, Désirée Larenas‐Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 262-272
Open Access | Times Cited: 24
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Carlo Lombardi, Pasquale Comberiati, Erminia Ridolo, et al.
Drugs (2024) Vol. 84, Iss. 6, pp. 661-684
Open Access | Times Cited: 9
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Wenjia Chen, Trung N. Tran, Mohsen Sadatsafavi, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2732-2747
Open Access | Times Cited: 18
Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps
Angélica Tiotiu, Nicolas Migueres, Francisco Javier González‐Barcala, et al.
Respiratory Medicine (2025) Vol. 238, pp. 107979-107979
Closed Access
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Trung N. Tran, Stephanie Chen, Benjamin Emmanuel, et al.
Pragmatic and Observational Research (2025) Vol. Volume 16, pp. 51-66
Open Access
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study
Claudia Crimi, Santi Nolasco, Alberto Noto, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 12, pp. 3315-3327
Open Access | Times Cited: 4
The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review
Junhui Ma, Qiang Ma, Jing Yang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The origins and longevity of IgE responses as indicated by serological and cellular studies in mice and humans
Zhoujie Ding, Jesse Mulder, M. Robinson
Allergy (2023) Vol. 78, Iss. 12, pp. 3103-3117
Open Access | Times Cited: 9
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Corrado Pelaia, Antonio Giacalone, Gianluca Ippolito, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 45-51
Open Access | Times Cited: 2
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review
Jonathan A. Bernstein, Jean‐Pierre Llanos, Gillian Hunter, et al.
Advances in Therapy (2023) Vol. 40, Iss. 11, pp. 4721-4740
Open Access | Times Cited: 5
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
Luis Pérez de Llano, Ghislaine Scélo, Giorgio Walter Canonica, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 5, pp. 610-622.e7
Open Access | Times Cited: 4
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study
Claudia Crimi, Santi Nolasco, Alberto Noto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study
Yen Chung, Diego J. Maselli, Fan Mu, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 954-962
Open Access | Times Cited: 2
Navigating the Terrain: Type 2 Cytokines and Biologic intervention in Severe Eosinophilic Asthma
Brian W. P. Seymour, Ashley A. Seymour, Patricia Gilford
IntechOpen eBooks (2024)
Open Access
Contemporary Concise Review 2023: Asthma
John D. Politis, Philip G. Bardin, Paul Leong
Respirology (2024) Vol. 29, Iss. 8, pp. 674-684
Open Access
Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study
S. Valéry, Stéfanie Habib-Maillard, Nicolás Roche
Respiratory Medicine and Research (2023) Vol. 84, pp. 101055-101055
Closed Access | Times Cited: 1
Page 1

Scroll to top